Tandem Diabetes Care (TNDM) PT Raised to $57 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Tandem Diabetes Care (TNDM) PT Raised to $56 at Piper Jaffray
September 26, 2018 6:20 AM EDTPiper Jaffray analyst JP McKim raised the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $56.00 (from $32.00) while maintaining a Overweight rating.
... MorePre-Open Movers 09/25: (ASNA) (TLRY) (NIHD) Higher; (TGTX) (OPNT) (SNDX) Lower (more...)
September 25, 2018 9:29 AM EDTToday's Pre-Open Movers
TG Therapeutics (NASDAQ: TGTX) 27.6% LOWER; announced that the independent Data Safety Monitoring Board (DSMB) for the UNITY-CLL Phase 3 trial met to review ongoing data from the study and advised the Company that the interim analysis of Overall... More
Tandem Diabetes (TNDM) Raises FY18 Sales Guidance
September 25, 2018 9:02 AM EDTTandem Diabetes Care®, Inc. (NASDAQ: TNDM) announced that it has increased its 2018 sales guidance to $150 million to $158 million, from $140 million to $148 million (*** consensus is $146.8 million), following continued strong domestic sales in the third quarter and the recent launch of the t:slim X2 Insulin Pump in select international markets. Compared to 2017 sales of approximately $108 million, the revised guidance... More
